The pharmaceutical industry has always been one of the largest investment-producing sectors, and with the development of technology and the growing demand for innovative therapies, this trend is reaching a new level. Successful projects that focus on the development of advanced drugs will not only demonstrate high profitability, but will also change the approach to the treatment of many illnesses. This article looks at the most promising innovative projects that have already returned significant investments and have become a standard of success.
One of the brightest applications of innovative success is the development of mRNA vaccines.
• BioNTech (Nimechina): In collaboration with Pfizer, the company developed one of the first mRNA vaccines for COVID-19. The project has cost over $1.3 billion in investment at the initial stages and has already brought in billions of dollars in profits. mRNA technology is now being considered for the treatment of cancer and infectious diseases.
• Moderna (USA): The company invested over $2.5 billion in the development of its mRNA technology. Its successful entry into the market not only solved the problem of the pandemic, but also laid the foundation for new research in the treatment of autoimmune diseases and rare diseases.
Why investors are focused on:
Gene therapy is changing the approach to the treatment of genetic diseases, introducing them outside the range of disease.
• Zolgensma (Novartis): Spinal musculoskeletal atrophy treatments have become one of the most expensive drugs in the world ($2.1 million per dose). The project received large-scale financial support from Novartis and became a revolutionary method for the treatment of rare diseases.
• Investments in the development of Zolgensma dropped to more than $8 billion, but sales of the drug largely recouped the costs, and the investment in gene therapy continues to grow.
Key benefits for investors:
Monoclonal antibodies play a key role in the treatment of cancer and autoimmune diseases.
• Regeneron Pharmaceuticals (USA): A leader in this category by investing in the development of the drug Dupixent for the treatment of asthma and eczema. Dupixent brought the company more than $8 billion in revenue in 2023 and continues to expand its indications until the end.
• The company also achieved success with monoclonal antibodies for the treatment of COVID-19, which received funding from the US under the Operation Warp Speed program.
Reasons for its popularity for investment:
Technologies that extract bacteria for disinfection are becoming a new trend in pharmacology.
• Seres Therapeutics (USA): The company invested over $500 million in the development of microbiome-based drugs that treat intestinal infections and restore the balance of microflora. Its first product, Vowst, will be praised by the FDA in 2023.
• The company’s share price increased significantly after the first successful clinical studies.
Advantages for investors:
CAR-T therapy has become a breakthrough in cancer treatment, opening up the possibility of personalized oncology.
• Yescarta (Gilead Sciences): A lymphoma treatment that boosts the patient’s immune cells to fight cancer.
• The project cost over $11 billion in investment, including the acquisition of Kite Pharma, the distributor of this technology. Yescarta has already brought the company over $1 billion in revenue per market.
Why investors are buying CAR-T:
Digital therapies have become a new direction that combines pharmacology and IT technologies.
• Pear Therapeutics (USA): The company develops digital supplements for the treatment of mental illness and mental disorders. Its first product, reSET, was praised by the FDA and rejected funding from venture capitalists.
• Pear Therapeutics spent $100 million to further develop digital solutions that will become part of complex therapy.
Advantages for investors:
Investments in innovative drugs offer investors great opportunities, due not only to high profitability, but also to social influx. Projects such as the development of mRNA vaccines, gene therapies or CAR-T therapies demonstrate how new technologies can radically change the approach to disease treatment. The choice of innovative directions is a strategy that will bring financial success to the future of medicine.
The technology of processing organic high-molecular waste and materials (plastics, solid alternative fuel TAT, sewage sludge) by thermal depolymerization is not new from the point of view of the physicochemical process – equipment for thermal processing of raw materials was used as early as 1938 in Germany and England.
Sources of solid waste generation are organizations and enterprises, the population of city districts, and infrastructure facilities. The population accounts for the maximum amount of solid waste generated.
In our removal method, contact with the therapeutic agent composition is prolonged, and the composition acts as an activator, provoking the body’s immune system response to activate phagocytosis.
Copyright © 2023 INSTITUTE OF NANOTECHNOLOGY AND ORGANIC PRODUCTS “AVELIFE”
